1. Home
  2. Live Updates
  3. புற்றுநோயியல் மருந்து

புற்றுநோயியல் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from புற்றுநோயியல் மருந்து. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In புற்றுநோயியல் மருந்து Today - Breaking & Trending Today

Oncology Pharma: Anleger sollten dies wissen! ()


02.07.21 01:37
Aktiennews
Oncology Pharma weist am 02.07.2021, 01:37 Uhr einen Kurs von 28.5 USD an der Börse auf. Das Unternehmen wird unter Edelmetalle und Mineralien geführt.
Auf Basis von insgesamt 4 Bewertungskriterien haben wir eine Einschätzung zum aktuellen Niveau für Oncology Pharma entwickelt. Auf jeder Stufe erhält das Unternehmen die Bewertung Buy , Hold bzw. Sell . Daraus resultiert in einer abschließenden Gewichtung die Gesamtnote.
1. Relative Strength Index: Auf Basis des Relative Strength-Index ist die Aktie der Oncology Pharma ein Hold-Titel. Der Index misst die Auf- und Abwärtsbewegungen verschiedener Zeiträume (RSI7 für sieben Tage, RSI25 für 25 Tage) und ordnet diesen eine Kennziffer zwischen 0 und 100 zu. Für die Oncology Pharma-Aktie ergibt sich ein Wert für den RSI7 von 84,53, was eine Sell -Empfehlung nach sich zieht, sowie ein Wert für den RSI25 von 42,5, der für diesen Zeitraum eine Hold -Einstufung bedingt. Daraus ....

Oncology Pharmaceuticals , Oncology Pharmaceutical , Company Will Receive , Relative Strength , Relative Strength Index , Oncology Pharmaceutical Gets , Distance From , Should Investors , Oday News , புற்றுநோயியல் மருந்துகள் , புற்றுநோயியல் மருந்து , உறவினர் வலிமை , உறவினர் வலிமை குறியீட்டு , தூரம் இருந்து , வேண்டும் முதலீட்டாளர்கள் , நாள் செய்தி ,

Oncology Pharma: Dies ist jetzt besonders wichtig ()

Oncology Pharma: Dies ist jetzt besonders wichtig ()
aktiencheck.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aktiencheck.de Daily Mail and Mail on Sunday newspapers.

Oncology Pharmaceuticals , Share Oncology Pharmaceuticals , Company Will Receive , Significant Changes , Mood Or Kommunikationsfrequenz , Relative Strength , Now For , Gives An Oncology , Weeks Have Been , Give Oncology , Should Investors , Oncology Pharmaceutical , Oday News , புற்றுநோயியல் மருந்துகள் , குறிப்பிடத்தக்க மாற்றங்கள் , உறவினர் வலிமை , இப்போது க்கு , வேண்டும் முதலீட்டாளர்கள் , புற்றுநோயியல் மருந்து , நாள் செய்தி ,

Novartis Pharma AG: Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

Tislelizumab demonstrated a 30% reduction in the risk of death and extended median overall survival by 2.3 months compared to chemotherapy in advanced or metastatic esophageal squamous cell carcinoma after ....

United States , Isabella Zinck , Jeff Legos , Thomas Hungerbuehler , Samir Shah , Mary Curtin Creaser , Julie Masow , Sloan Simpson , Jaffer Ajani , National Cancer Institute , American Society Of Clinical Oncology , University Of Texas Md Anderson Cancer Center , Virtual Scientific Program , Novartis Us External Communications , Novartis External Communications , Exchange Commission , American Society Of Clinical Oncology Annual Meeting , Head Of Oncology Drug Development , Clinical Oncology , Senior Vice President , Oncology Drug , Gastrointestinal Medical Oncology , Scientific Program , North America , Kims B , American Society ,

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy ....

United States , Isabella Zinck , Jeff Legos , Thomas Hungerbuehler , Samir Shah , Mary Curtin Creaser , Julie Masow , Sloan Simpson , Jaffer Ajani , National Cancer Institute , American Society Of Clinical Oncology , University Of Texas Md Anderson Cancer Center , Virtual Scientific Program , Novartis Us External Communications , Novartis External Communications , Exchange Commission , American Society Of Clinical Oncology Annual Meeting , Head Of Oncology Drug Development , Clinical Oncology , Senior Vice President , Oncology Drug , Gastrointestinal Medical Oncology , Scientific Program , North America , Kims B , American Society ,

Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

/PRNewswire/ Novartis announced today results from the pivotal Phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint. ....

United States , Mary Curtin Creaser , Jeff Legos , Julie Masow , Sloan Simpson , Jaffer Ajani , National Cancer Institute , American Society Of Clinical Oncology , University Of Texas Md Anderson Cancer Center , Virtual Scientific Program , Exchange Commission , American Society Of Clinical Oncology Annual Meeting , Head Of Oncology Drug Development , Novartis Pharmaceuticals Corporation , Nj Novartis Pharmaceuticals Corporation , Clinical Oncology , Senior Vice President , Oncology Drug , Gastrointestinal Medical Oncology , Scientific Program , North America , East Hanover , Pharmaceuticals Corporation , Kims B , American Society , Clinical Oncology Annual Meeting ,